Pfizer Inc.
Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
Last updated:
Abstract:
The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
Status:
Grant
Type:
Utility
Filling date:
5 Dec 2016
Issue date:
13 Jul 2021